Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BISSERY MC' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 34 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bissery, MC
      Preclinical evaluation of new taxoids

      CURRENT PHARMACEUTICAL DESIGN
    2. Campone, M; Fumoleau, P; Delecroix, V; Deporte-Fety, R; Perrocheau, G; Vernillet, L; Borg-Olivier, O; Louboutin, JP; Bissery, MC; Riva, A; Azli, N
      Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer

      ANNALS OF ONCOLOGY
    3. Granda, TG; Filipski, E; D'Attino, RM; Vrignaud, P; Anjo, A; Bissery, MC; Levi, F
      Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination

      CANCER RESEARCH
    4. Mailliet, P; Laoui, A; Bourzat, JD; Capet, M; Cheve, M; Commercon, A; Dereu, N; LeBrun, A; Martin, JP; Peyronel, JF; Salagnad, C; Thompson, F; Zucco, M; Guitton, JD; Pantel, G; Bissery, MC; Brealey, C; Lavayre, J; Lelievre, Y; Riou, JF; Vrignaud, P; Duchesne, M; Lavelle, F
      From random screening of chemical libraries to the optimization of FPP-Competitive inhibitors of farnesyltransferase

      FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY
    5. Veitia, R; David, S; Barbier, P; Vantard, M; Gounon, P; Bissery, MC; Fellous, A
      Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel

      BRITISH JOURNAL OF CANCER
    6. Veitia, RA; Ottolenghi, C; Bissery, MC; Fellous, A
      A novel human gene, encoding a potential membrane protein conserved from yeast to man, is strongly expressed in testis and cancer cell lines

      CYTOGENETICS AND CELL GENETICS
    7. TAMPELLINI M; FILIPSKI E; LIU XH; LEMAIGRE G; LI XM; VRIGNAUD P; FRANCOIS E; BISSERY MC; LEVI F
      DOCETAXEL CHRONOPHARMACOLOGY IN MICE

      Cancer research
    8. VELTIA R; BISSERY MC; MARTINEZ C; FELLOUS A
      TAU EXPRESSION IN MODEL ADENOCARCINOMAS CORRELATES WITH DOCETAXEL SENSITIVITY IN TUMOR-BEARING MICE

      British Journal of Cancer
    9. BISSERY MC; VRIGNAUD P; LAVELLE F
      IN-VIVO EVALUATION OF THE IRINOTECAN-OXALIPLATIN COMBINATION

      European journal of cancer
    10. VASSAL G; BOLAND I; SANTOS A; BISSERY MC; TERRIERLACOMBE MJ; MORIZET J; SAINTEROSE C; LELLOUCHTUBIANA A; KALIFA C; GOUYETTE A
      POTENT THERAPEUTIC ACTIVITY OF IRINOTECAN (CPT-11) AND ITS SCHEDULE DEPENDENCY IN MEDULLOBLASTOMA XENOGRAFTS IN NUDE-MICE

      International journal of cancer
    11. BISSERY MC; VRIGNAUD P; LAVELLE F; CHABOT GG
      EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE

      Anti-cancer drugs
    12. ABIGERGES D; ARMAND JP; CHABOT GG; BRUNO R; BISSERY MC; BAYSSAS M; KLINKALAKL M; CLAVEL M; CATIMEL G
      PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS

      Anti-cancer drugs
    13. FROMES Y; GOUNON P; VEITIA R; BISSERY MC; FELLOUS A
      INFLUENCE OF MICROTUBULE-ASSOCIATED PROTEINS ON THE DIFFERENTIAL-EFFECTS OF PACLITAXEL AND DOCETAXEL

      Journal of protein chemistry
    14. LORUSSO PM; DEMCHIK L; FOSTER B; KNIGHT J; BISSERY MC; POLIN LM; LEOPOLD WR; CORBETT TH
      PRECLINICAL ANTITUMOR-ACTIVITY OF CI-994

      Investigational new drugs
    15. LAVELLE F; BISSERY MC; ANDRE S; ROQUET F; RIOU JF
      PRECLINICAL EVALUATION OF CPT-11 AND ITS ACTIVE METABOLITE SN-38

      Seminars in oncology
    16. OJIMA I; SLATER JC; MICHAUD E; KUDUK SD; BOUNAUD PY; VRIGNAUD P; BISSERY MC; VEITH JM; PERA P; BERNACKI RJ
      SYNTHESES AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE 2ND-GENERATION ANTITUMOR TAXOIDS - EXCEPTIONAL ACTIVITY AGAINST DRUG-RESISTANT CANCER-CELLS

      Journal of medicinal chemistry
    17. VASSAL G; TERRIERLACOMBE MJ; BISSERY MC; VENUAT AM; GYERGYAY F; BENARD J; MORIZET J; BOLAND I; ARDOUIN P; BRESSACDEPAILLERETS B; GOUYETTE A
      THERAPEUTIC ACTIVITY OF CPT-11, A DNA-TOPOISOMERASE-I INHIBITOR, AGAINST PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR AND NEUROBLASTOMA XENOGRAFTS

      British Journal of Cancer
    18. BISSERY MC
      PRECLINICAL PHARMACOLOGY OF DOCETAXEL

      European journal of cancer
    19. BISSERY MC; NOHYNEK G; SANDERINK GJ; LAVELLE F
      DOCETAXEL (TAXOTERE(R)) - A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .1. PRECLINICAL EXPERIENCE

      Anti-cancer drugs
    20. NGUYEN CH; FAN E; RIOU JF; BISSERY MC; VRIGNAUD P; LAVELLE F; BISAGNI E
      SYNTHESIS AND BIOLOGICAL EVALUATION OF AMINO-SUBSTITUTED BENZO[F]PYRIDO[4,3-B] AND PYRIDO[3,4-B]QUINOXALINES - A NEW CLASS OF ANTINEOPLASTIC AGENTS

      Anti-cancer drug design
    21. MAILLIET P; SEGALBENDIRDJIAN E; KOZELKA J; BARREAU M; BAUDOIN B; BISSERY MC; GONTIER S; LAOUI A; LAVELLE F; LEPECQ JB; CHOTTARD JC
      ASYMMETRICALLY SUBSTITUTED ETHYLENEDIAMINE PLATINUM(II) COMPLEXES AS ANTITUMOR AGENTS - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS

      Anti-cancer drug design
    22. DYKES DJ; BISSERY MC; HARRISON SD; WAUD WR
      RESPONSE OF HUMAN TUMOR XENOGRAFTS IN ATHYMIC NUDE-MICE TO DOCETAXEL (RP-56976, TAXOTERE(R))

      Investigational new drugs
    23. BISSERY MC; VRIGNAUD P; LAVELLE F
      PRECLINICAL PROFILE OF DOCETAXEL (TAXOTERE) - EFFICACY AS A SINGLE-AGENT AND IN COMBINATION

      Seminars in oncology
    24. LAVELLE F; BISSERY MC; COMBEAU C; RIOU JF; VRIGNAUD P; ANDRE S
      PRECLINICAL EVALUATION OF DOCETAXEL (TAXOTERE)

      Seminars in oncology
    25. MASSAAD L; CHABOT GG; TOUSSAINT C; KOSCIELNY S; MORIZET J; BISSERY MC; GOUYETTE A
      INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38

      Cancer chemotherapy and pharmacology
    26. RIBRAG V; MASSAAD L; JANOT F; BISSERY MC; PARISE O; GOUYETTE A; CHABOT GG
      PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO

      Leukemia research
    27. OJIMA I; DUCLOS O; ZUCCO M; BISSERY MC; COMBEAU C; VRIGNAUD P; RIOU JF; LAVELLE F
      SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NEW ANTITUMOR TAXOIDS - EFFECTS OF CYCLOHEXYL SUBSTITUTION AT THE C-3' AND OR C-2 OF TAXOTERE (DOCETAXEL)/

      Journal of medicinal chemistry
    28. ECKARDT JR; BURRIS HA; KUHN JG; BISSERY MC; KLINKALAKL M; CLARK GM; VONHOFF DD
      ACTIVITY OF INTOPLICINE (RP60475), A NEW DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO

      Journal of the National Cancer Institute
    29. MAURER HR; ECKERT K; BISSERY MC
      TAXOTERE(R) INHIBITS THE PROLIFERATION AND INDUCES THE DIFFERENTIATION OF HL-60 AND K562 HUMAN MYELOID-LEUKEMIA CELLS IN-VITRO

      International journal of oncology
    30. VOGEL M; HILSENBECK SG; DEPENBROCK H; DANHAUSERRIEDL S; BLOCK T; NEKARDA H; FELLBAUM C; AAPRO MS; BISSERY MC; RASTETTER J; HANAUSKE AR
      PRECLINICAL ACTIVITY OF TAXOTERE (RP-56976, NSC-628503) AGAINST FRESHLY EXPLANTED CLONOGENIC HUMAN TUMOR-CELLS - COMPARISON WITH TAXOL AND CONVENTIONAL ANTINEOPLASTIC AGENTS

      European journal of cancer
    31. BOVEN E; VENEMAGABERSCEK E; ERKELENS CAM; BISSERY MC; PINEDO HM
      ANTITUMOR-ACTIVITY OF TAXOTERE (RP-56976, NSC-628503), A NEW TAXOL ANALOG, IN EXPERIMENTAL OVARIAN-CANCER

      Annals of oncology
    32. BISSERY MC; NGUYEN CH; BISAGNI E; VRIGNAUD P; LAVELLE F
      ANTITUMOR-ACTIVITY OF INTOPLICINE (RP-60475, NSC-645008), A NEW BENZOPYRIDO-INDOLE - EVALUATION AGAINST SOLID TUMORS AND LEUKEMIAS IN MICE

      Investigational new drugs
    33. RIOU JF; FOSSE P; NGUYEN CH; LARSEN AK; BISSERY MC; GRONDARD L; SAUCIER JM; BISAGNI E; LAVELLE F
      INTOPLICINE (RP-60475) AND ITS DERIVATIVES, A NEW CLASS OF ANTITUMOR AGENTS INHIBITING BOTH TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITIES

      Cancer research
    34. HOUGHTON PJ; CHESHIRE PJ; HALLMAN JC; BISSERY MC; MATHIEUBOUE A; HOUGHTON JA
      THERAPEUTIC EFFICACY OF THE TOPOISOMERASE-I INHIBITOR PIPERIDINO]-1-PIPERIDINO)-CARBONYLOXY-CAMPTOTHECIN AGAINST HUMAN TUMOR XENOGRAFTS - LACK OF CROSS-RESISTANCE INVIVO IN TUMORS WITH ACQUIRED-RESISTANCE TO THE TOPOISOMERASE-I INHIBITOR 9-DIMETHYLAMINOMETHYL-10-HYDROXYCAMPTOTHECIN

      Cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 11:34:21